IP
TOVX icon

Intellectus Partners’s Theriva Biologics TOVX Stock Holding History

Intellectus Partners’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed -$1K – 487
2018
Q3 		$1K Hold
1
– – ﹤0.01% 565
2018
Q2 		$2K Hold
1
– – ﹤0.01% 567
2018
Q1 		$3K Hold
1
– – ﹤0.01% 555
2017
Q4 		$5K Hold
1
– – ﹤0.01% 550
2017
Q3 		$9K Hold
1
– – ﹤0.01% 628
2017
Q2 		$5K Hold
1
– – ﹤0.01% 672
2017
Q1 		$6K Hold
1
– – ﹤0.01% 581
2016
Q4 		$7K Buy
+1
New +$10.3K ﹤0.01% 557

Other funds holding TOVX

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Intellectus Partners's TOVX Position: Q4 2018 in Review

Intellectus Partners sold out of Theriva Biologics (TOVX) in Q4 2018, closing a stake of 1 share — an estimated $1K sold.

Intellectus Partners first reported a position in TOVX in Q4 2016 and held it in 8 quarters. The position peaked at $9K in Q3 2017. 23 funds tracked by Wall St. Rank hold TOVX as of Q4 2018.

  • Intellectus Partners reported no remaining Theriva Biologics position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 1 Theriva Biologics share in Q4 2018, an estimated $1K.
  • Intellectus Partners first reported a position in Theriva Biologics in Q4 2016 and held it in 8 quarters.
  • Intellectus Partners's Theriva Biologics position peaked at $9K in Q3 2017.
  • 23 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.